RxDoctor Payments Data

Mary Bacon

Family · Pembroke, NHNPI 1245399930

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.7% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,976in general payments, 2019–2025

Across 144 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$601
  • Lilly USA, LLC$394
  • Merck$276
  • AstraZeneca$270
  • Boehringer Ingelheim$229
  • Astellas Pharma US Inc$215
  • plus $991 from 19 others

What the payments were for

  • Food & beverage$2,73092%
  • Education$2468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,976 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$37,987
Medicare patients
63
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$17,947
OzempicSemaglutide14$16,727
XareltoRivaroxaban12$15,882
FarxigaDapagliflozin Propanediol13$8,600
Breo ElliptaFluticasone/Vilanterol11$4,424
VyvanseLisdexamfetamine Dimesylate11$4,165
SymbicortBudesonide/Formoterol Fumarate12$3,427
Potassium Chloride26$1,190
Memantine Hcl ErMemantine Hcl14$1,186
Gabapentin27$1,134
Paroxetine ErParoxetine Hcl17$901
Bupropion XlBupropion Hcl24$659
Levothyroxine Sodium69$652
Albuterol Sulfate HfaAlbuterol Sulfate38$627
Atorvastatin Calcium96$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$229$17,94713 claims
Novo NordiskOzempic$601$16,72714 claims
Johnson & JohnsonXarelto$21$15,88212 claims
AstraZenecaFarxiga, Symbicort$270$12,02725 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$37$4,16511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.

Other family in Pembroke

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →